Advertisement

Acute promyelocytic leukemia and constitutional trisomy 21

  • Carla Kurkjian
    Affiliations
    Section of Hematology-Oncology and OU Cancer Center, University of Oklahoma Health Sciences Center, 920 Stanton L. Young Boulevard, WP 2080, Oklahoma City, OK 73104

    Medical Services, Veterans Affairs Medical Center, Oklahoma City, OK
    Search for articles by this author
  • Sunil Patel
    Affiliations
    Section of Hematology-Oncology and OU Cancer Center, University of Oklahoma Health Sciences Center, 920 Stanton L. Young Boulevard, WP 2080, Oklahoma City, OK 73104
    Search for articles by this author
  • Rammurti Kamble
    Affiliations
    Section of Hematology-Oncology and OU Cancer Center, University of Oklahoma Health Sciences Center, 920 Stanton L. Young Boulevard, WP 2080, Oklahoma City, OK 73104

    Medical Services, Veterans Affairs Medical Center, Oklahoma City, OK
    Search for articles by this author
  • S. Terrence Dunn
    Affiliations
    Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK
    Search for articles by this author
  • William Kern
    Affiliations
    Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK
    Search for articles by this author
  • Mohamed A. Kharfan-Dabaja
    Correspondence
    Corresponding author. Tel.: (813) 745-8248; fax: (813) 979-3071.
    Affiliations
    Section of Hematology-Oncology and OU Cancer Center, University of Oklahoma Health Sciences Center, 920 Stanton L. Young Boulevard, WP 2080, Oklahoma City, OK 73104

    Medical Services, Veterans Affairs Medical Center, Oklahoma City, OK
    Search for articles by this author

      Abstract

      The incidence of acute myelogenous leukemia (AML) in patients with constitutional trisomy 21 is estimated to be 1 in 300; it is usually seen before age four. Clinical and epidemiological data confirm the improved life expectancy of patients with Down syndrome and their increased susceptibility to the development of leukemia, among other cancers. The most frequent subtype of AML associated with Down syndrome is acute megakaryoblastic leukemia (FAB: M7). The description of acute promyelocytic leukemia (APL) in adult patients with Down syndrome is exceedingly rare. Herein, we describe the unusual presentation, treatment, results, and clinical course of an adult patient with APL and constitutional trisomy 21 and provide a brief review of the literature.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Cancer Genetics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • de Botton S.
        • Coiteux V.
        • Chevret S.
        • Rayon C.
        • Vilmer E.
        • Sanz M.
        • de La Serna J.
        • Philippe N.
        • Baruchel A.
        • Leverger G.
        • Robert A.
        • San Miguel J.
        • Conde E.
        • Sotto J.
        • Bordessoule D.
        • Fegueux N.
        • Fey M.
        • Parry A.
        • Chomienne C.
        • Degos L.
        • Fenzux P.
        Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy.
        J Clin Oncol. 2004; 22: 1404-1412
        • Stone R.M.
        • Mayer R.J.
        The unique aspects of acute promyelocytic leukemia.
        J Clin Oncol. 1990; 8: 1913-1921
        • Warrell Jr., R.P.
        • de The H.
        • Wang Z.Y.
        • Degos L.
        Acute promyelocytic leukemia.
        N Engl J Med. 1993; 329: 177-189
        • Spell D.W.
        • Velagaleti G.V.N.
        • Jones D.V.
        • Velasquez W.S.
        Translocation (15:17) and trisomy 21 in the microgranular variant of acute promyelocytic leukemia.
        Cancer Genet Cytogenet. 2002; 132: 74-76
        • Osella P.
        • Wyandt H.
        • Vosburgh E.
        • Milunsky A.
        Report of a variant t(1;15;17)(p36;q22;q21.1) in a patient with acute promyelocytic leukemia.
        Cancer Genet Cytogenet. 1991; 57: 201-207
        • Miura I.
        • Nishinari T.
        • Hashimoto K.
        • Nimura T.
        • Miura S.
        • Miura A.B.
        Translocation (8;17)(p21;q21), a possible variant of t(15;17), in acute promyelocytic leukemia.
        Cancer Genet Cytogenet. 1994; 72: 75-77
        • Gamis A.S.
        • Woods W.G.
        • Alonzo T.A.
        • Buxton A.
        • Lange B.
        • Barnard D.R.
        • Gold S.
        • Smith F.O.
        Increased age at diagnosis has a significantly negative effect on outcome in children with down syndrome and acute myeloid leukemia: a report from the children's cancer group study 2891.
        J Clin Oncol. 2003; 21: 3415-3422
        • Lange B.J.
        • Kobrinsky N.
        • Barnard D.R.
        • Arthur D.C.
        • Buckley J.D.
        • Howells W.B.
        • Gold S.
        • Sanders J.
        • Neudorf S.
        • Smith F.O.
        • Woods W.G.
        Distinctive demography, biology and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with down syndrome: Children's Cancer Group studies 2861 and 2891.
        Blood. 1998; 91: 608-615
        • Sanz M.A.
        • Martín G.
        • González M.
        • León A.
        • Rayón C.
        • Rivas C.
        • Colomer D.
        • Amutio E.
        • Capote F.J.
        • Milone G.A.
        • de la Serna J.
        • Roman J.
        • Barragán E.
        • Bergua J.
        • Escoda L.
        • Parody R.
        • Negri S.
        • Calasanz M.J.
        • Bolufer P.
        Programa de Estudio y Tratamiento de las Hemopatías Malignas. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group.
        Blood. 2004; 103: 1237-1243
        • Gamis A.S.
        Acute myeloid leukemia and Down syndrome evolution of modern therapy: state of the art review.
        Pediatr Blood Cancer. 2005; 44: 13-20
        • Ge Y.
        • Stout M.L.
        • Tatman D.A.
        • Jensen T.L.
        • Buck S.
        • Thomas R.L.
        • Ravindranath Y.
        • Matherly L.H.
        • Taub J.W.
        GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia.
        J Natl Cancer Inst. 2005; 97: 226-231
        • Yang Q.
        • Rasmussen S.A.
        • Friedman J.M.
        Mortality associated with Down syndrome in the USA from 1983 to 1997: a population-based study.
        Lancet. 2002; 359: 1019-1025
        • Goldacre M.J.
        • Wotton C.J.
        • Seagroatt V.
        • Yeates D.
        Cancers and immune related diseases associated with Down syndrome: a record linkage study.
        Arch Dis Child. 2004; 89: 1014-1017
        • Grimwade D.
        • Gorman P.
        • Duprez E.
        • Howe K.
        • Langabeer S.
        • Oliver F.
        • Walker H.
        • Culligan D.
        • Waters J.
        • Pomfret M.
        • Goldstone A.
        • Burnett A.
        • Freemont P.
        • Sheer D.
        • Solomon E.
        Characterization of cryptic rearrangements and variant translocations in patients with acute promyelocytic leukemia.
        Blood. 1997; 90: 4876-4885
        • Chauffaille M.L.
        • Figueiredo M.S.
        • Beltrani R.
        • Antunes S.V.
        • Yamamoto M.
        • Kerbauy J.
        Acute promyelocytic leukemia: the study of t(15;17) translocation by fluorescent in situ hybridization, reverse transcriptase-polymerase chain reaction and cytogenetic techniques.
        Braz J Med Biol Res. 2001; 34: 735-743
        • Zaccaria A.
        • Valenti A.
        • Toschi M.
        • Salvucci M.
        • Cipriani R.
        • Ottaviani E.
        • Martinelli G.
        Cryptic translocation of PML/RARA on 17q: a rare event in acute promyelocytic leukemia.
        Cancer Genet Cytogenet. 2002; 138: 169-173
        • Shivakumar S.
        • Poonkhuzhali B.
        • Gunasekaran S.
        • Srivastava A.
        • Chandy M.
        Cytogenetic, fluorescent in situ hybridization & reverse transcriptase-polymerase chain reaction analysis in acute promyelocytic leukaemia patients.
        Indian J Med Res. 2002; 115: 59-67
        • Miller Jr., W.H.
        • Kakizuka A.
        • Frankel S.R.
        • Warrell Jr., R.P.
        • DeBlasio A.
        • Levine K.
        • Evans R.M.
        • Dmitrovsky E.
        Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor α clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia.
        Proc Natl Acad Sci U S A. 1992; 89: 2694-2698
        • Singal U.
        • Shah-Reddy I.
        • Koppitch F.
        Trisomy 21 in acute promyelocytic leukemia.
        Tumori. 1987; 73: 403-406
        • Cortes J.E.
        • Kantarjian H.
        • O'Brien S.
        • Keating M.
        • Pierce S.
        • Freireich E.J.
        • Estey E.
        Clinical and prognostic significance of trisomy 21 in adult patients with acute myelogenous leukemia and myelodysplastic syndromes.
        Leukemia. 1995; 9: 115-117